|
WO2014204417A1
|
|
Inhalation device comprising a flexible plate
|
|
WO2014062143A2
|
|
Combinations of glycopyrrolate and an anticholinergic agent
|
|
WO2014077787A1
|
|
Combinations including abeta2 agonist and glycopyrrolate
|
|
WO2014051532A1
|
|
Pharmaceutical tablet formulations comprising cefdinir
|
|
WO2014042605A1
|
|
New tiotropium bromide crystalline form
|
|
WO2014035355A1
|
|
Pharmaceutical combination comprising idebenone and memantine
|
|
WO2014035356A1
|
|
Tablet formulations comprising a quinone derivative active agent
|
|
WO2014055047A1
|
|
Combination of idebenone and donezepil
|
|
WO2014014427A1
|
|
Modified release pharmaceutical tablet formulations
|
|
WO2014007775A1
|
|
A novel formulation having fast dissolution
|
|
WO2014007774A1
|
|
Water soluble formulations comprising a piperidine derivative active agent
|
|
WO2014007776A1
|
|
Antispasmodic modified release formulations
|
|
WO2013180676A1
|
|
A new sustained release formulation
|
|
WO2013180675A1
|
|
Tablet formulation comprising dapoxetine
|
|
WO2013169218A1
|
|
Pharmaceutical compositions of s-etodolac
|
|
WO2013172805A1
|
|
New orodispersible tablet formulations of olanzapine
|
|
WO2013165330A1
|
|
Stable effervescent formulations
|
|
WO2013165327A1
|
|
Pharmaceutical formulations comprising thiocolchicoside
|
|
WO2013154511A1
|
|
Film tablet formulations comprising dexibuprofen
|
|
EP2833874A1
|
|
Capsule formulations comprising ceftibuten
|
